Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale
July 28, 2015 9:13 AM EDTCanaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More
Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement
July 28, 2015 8:19 AM EDTAllergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.
Gerberry... More
